347 related articles for article (PubMed ID: 16467555)
1. Trastuzumab in breast cancer.
Gilbert SG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
[No Abstract] [Full Text] [Related]
2. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Seidman AD
Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
[No Abstract] [Full Text] [Related]
3. Trastuzumab in breast cancer.
Banna GL; Santoro A
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
[No Abstract] [Full Text] [Related]
4. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
5. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
6. Trastuzumab in breast cancer.
Gounaris IG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
[No Abstract] [Full Text] [Related]
7. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
8. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
Dent R; Clemons M
Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
[No Abstract] [Full Text] [Related]
9. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
10. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
12. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
13. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
14. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice.
Goel S; Beith JM
J Clin Oncol; 2011 Mar; 29(7):e175-6. PubMed ID: 21189375
[No Abstract] [Full Text] [Related]
15. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
17. Update on administration of adjuvant trastuzumab.
McArthur HL
Clin Adv Hematol Oncol; 2010 May; 8(5):321-2, 375. PubMed ID: 20551890
[No Abstract] [Full Text] [Related]
18. Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority.
Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17582927
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab--mechanism of action and use.
Mir O; Berveiller P; Pons G
N Engl J Med; 2007 Oct; 357(16):1664-5; author reply 1665-6. PubMed ID: 17948347
[No Abstract] [Full Text] [Related]
20. [Medical treatment of primary breast cancer: new targeted biological treatments].
Andersson M; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3082-4. PubMed ID: 17877953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]